Hepion Pharma Appoints New Officers, Clinical Data Expected Q3
Ticker: CTRVP · Form: 8-K · Filed: Jun 30, 2025 · CIK: 1583771
| Field | Detail |
|---|---|
| Company | Hepion Pharmaceuticals, Inc. (CTRVP) |
| Form Type | 8-K |
| Filed Date | Jun 30, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, clinical-trial, drug-development
TL;DR
Hepion Pharma names new CMO/CSO, CRV417 data due Q3 2025.
AI Summary
On June 25, 2025, Hepion Pharmaceuticals, Inc. announced changes to its board of directors and executive compensation. Dr. D. R. Ramakrishna was appointed as Chief Medical Officer, and Dr. Michael J. Sofia was appointed as Chief Scientific Officer. The company also reported on its ongoing clinical trials for its liver disease drug, CRV417, with preliminary data expected in Q3 2025.
Why It Matters
The appointment of new key officers and the upcoming clinical trial data could significantly impact Hepion's drug development pipeline and future market position.
Risk Assessment
Risk Level: medium — The company is in the clinical trial phase for a drug, which carries inherent risks of trial failure and regulatory hurdles.
Key Numbers
- Q3 2025 — Data Release (Preliminary data for CRV417 expected)
Key Players & Entities
- Hepion Pharmaceuticals, Inc. (company) — Registrant
- Dr. D. R. Ramakrishna (person) — Appointed Chief Medical Officer
- Dr. Michael J. Sofia (person) — Appointed Chief Scientific Officer
- CRV417 (drug) — Drug in clinical trials
- June 25, 2025 (date) — Date of earliest event reported
- Q3 2025 (date) — Expected data release timeframe
FAQ
What specific liver diseases is CRV417 intended to treat?
The filing does not specify the exact liver diseases CRV417 is intended to treat, but it is generally discussed in the context of liver disease drug development.
What were the previous roles of Dr. D. R. Ramakrishna and Dr. Michael J. Sofia?
The filing does not detail the previous roles of Dr. D. R. Ramakrishna and Dr. Michael J. Sofia prior to their appointments.
What is the expected timeline for the preliminary data release for CRV417?
Preliminary data for CRV417 is expected in the third quarter of 2025 (Q3 2025).
Has Hepion Pharmaceuticals, Inc. undergone any name changes previously?
Yes, Hepion Pharmaceuticals, Inc. was formerly known as ContraVir Pharmaceuticals, Inc., with a name change date of August 6, 2013.
What is the principal executive office address for Hepion Pharmaceuticals, Inc.?
The principal executive offices are located at 55 Madison Ave., Suite 400- PMB# 4362, Morristown, NJ 07960.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 30, 2025 by Dr. D. R. Ramakrishna regarding Hepion Pharmaceuticals, Inc. (CTRVP).